Bitter melon extracts and cucurbitane-type triterpenoid glycosides antagonize lipopolysaccharide-induced inflammation via suppression of NLRP3 inflammasome

Bitter melon (Momordica charantia L.) has been used to manage diabetes and various inflammatory conditions. While studies have explored the use of bitter melon to manage these conditions, the bioactive components and molecular mechanisms mediating the anti-inflammatory effects remain elusive. In the current study, acetone and methanol extracts of bitter melon along with purified compounds (momordicoside A, momordicoside L, karaviloside VI, karaviloside VIII, and charantoside XV) from acetone extract were screened using RAW 264.7 macrophage cells. Acetone and methanol extracts decreased LPS-induced expression of genes related to the formation of the inflammasome complex (NF-KB, NLRP3, Pycard, Casp1). The purified triterpenoids had differential anti-inflammatory effects on the expression of the genes IL-1 beta, NF-KB, NLRP3, Pycard, Casp1, HMGB1, and HMOX-1. Additionally, molecular docking data suggest that these molecules may be a potent inhibitor of NF-Kappa B. Taken together, the five bioactive compounds exerted anti-inflammatory effects in LPS-induced inflammation, likely via suppression of the NF-KB-NLRP3 pathway.

Automated summary

The study found that bioactive compounds found in bitter melon, such as momordicoside A, momordicoside L, karaviloside VI, karaviloside VIII, and charantoside XV, exhibited anti-inflammatory effects in LPS-induced inflammation, possibly by suppressing the NF-KB-NLRP3 pathway.